<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01504503</url>
  </required_header>
  <id_info>
    <org_study_id>645/09</org_study_id>
    <nct_id>NCT01504503</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study for Donepezil Hydrochloride 10 mg Tablets Under Fasting Condition</brief_title>
  <official_title>Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Donepezil Hydrochloride Tablets 10mg With ARICEPT® (Containing Donepezil Hydrochloride) Tablets 10 mg in Healthy, Adult, Human Subjects Under Fasting Condition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, balanced, randomized, two-treatment, two-period, two sequence, single&#xD;
      dose, crossover, oral bioequivalence study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was an open label, balanced, randomized, two-treatment, two-period, two&#xD;
      sequence,single dose, crossover, oral bioequivalence study of Donepezil Hydrochloride tablets&#xD;
      10 mg of Dr. Reddy's Laboratories Limited, India comparing with that of ARICEPT® (containing&#xD;
      Donepezil Hydrochloride) tablets 10 mg of Pfizer Inc, New York, 10017 in healthy, adult,&#xD;
      human subjects under fasting condition. 28 subjects are enrolled in the study, and 26&#xD;
      subjects are completed the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area unde curve (AUC)</measure>
    <time_frame>Pre-dose 0.5,0.75,1,1.5,2,2.5,3,3.5,4,4.5,5,5.5,6,7,8,9,10,12,16,24,36,48,72,96,120,144,168,192,216,240 and 264 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Donepezil Hydrochloride10 mg Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aricept 10 mg Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aricept 10 mgTablets of Pfizer Inc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil Hydrochloride</intervention_name>
    <description>Donepezil Hydrochloride Tablets 10 mg</description>
    <arm_group_label>Donepezil Hydrochloride10 mg Tablets</arm_group_label>
    <other_name>Aricept 10 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aricept</intervention_name>
    <description>Aricept 10 mg Tablets</description>
    <arm_group_label>Aricept 10 mg Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide written informed consent.&#xD;
&#xD;
          -  Must be healthy, adult, human beings within 18 and 45 years of age (both inclusive)&#xD;
             weighing at least 50 kg.&#xD;
&#xD;
          -  Having a body mass index between 18.0 and 24.9 (both inclusive), calculated as weight&#xD;
             in Kg/height in m2.&#xD;
&#xD;
          -  Must be of normal health as determined by medical history, physical examination and&#xD;
             laboratory investigation performed within 28 days prior to the commencement of the&#xD;
             study. (Laboratory values must be within normal limits or considered by the physician&#xD;
             / investigator to be of no clinical significance).&#xD;
&#xD;
          -  Female Subjects&#xD;
&#xD;
               -  Of child bearing potential practicing an acceptable method of birth control for&#xD;
                  the duration of the study as judged by the investigator(s), such as condoms,&#xD;
                  foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.&#xD;
&#xD;
               -  Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or&#xD;
                  hysterectomy has been performed on the subject)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Incapable of understanding the informed consent.&#xD;
&#xD;
          -  Systolic blood pressure less than 90 mm of Hg 140 mm of Hg.&#xD;
&#xD;
          -  Diastolic blood pressure less than 60 mm of Hg 90 mm of Hg.&#xD;
&#xD;
          -  Oral temperature is below 95.0°F or above 98.6°F.&#xD;
&#xD;
          -  Pulse rate below 50/min or above 100/min.&#xD;
&#xD;
          -  History of hypersensitivity or idiosyncratic reaction to investigational drug product&#xD;
             or any other related drugs.&#xD;
&#xD;
          -  Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal&#xD;
             function.&#xD;
&#xD;
          -  Consumption of grapefruit for the past ten days prior to the check-in, in each period.&#xD;
&#xD;
          -  Regular smoker who has a habit of smoking more than nine cigarettes per day and has&#xD;
             difficulty in abstaining from smoking during sample collection period.&#xD;
&#xD;
          -  Habit of alcoholism and difficulty in abstaining from alcohol during the sample&#xD;
             collection period.&#xD;
&#xD;
          -  Difficulty in abstaining from xanthene containing food or beverages (like tea, coffee,&#xD;
             chocolates and cola drinks) during the sample collection period.&#xD;
&#xD;
          -  Intake of over the counter (OTC) or prescribed medications and enzyme modifying&#xD;
             medication or systemic medication for the last 30 days before dosing.&#xD;
&#xD;
          -  Clinically significant abnormalities and / or with significant diseases.&#xD;
&#xD;
          -  Confirmed positive in alcohol screening.&#xD;
&#xD;
          -  Confirmed positive in selected drug of abuse.&#xD;
&#xD;
          -  Participated in any other clinical investigation using experimental drug/donated blood&#xD;
             in past 90 days before the date of start of study.&#xD;
&#xD;
          -  Confirmed positive in urine pregnancy test.&#xD;
&#xD;
          -  Female detected to be pregnant, breast feeding or who is likely to become pregnant&#xD;
             during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. L Krishna Murthy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bioserve Clinical Research Private Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bioserve Clinical Research Private Limited</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>January 3, 2012</study_first_submitted>
  <study_first_submitted_qc>January 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2012</study_first_posted>
  <last_update_submitted>January 5, 2012</last_update_submitted>
  <last_update_submitted_qc>January 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Donepezil</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

